E-LIB Suche - Ergebnisse für: Fong, C.

1

Pembrolizumab and Enzalutamide in Patients with Abiraterone..:

Yu, Evan Y. ; Berry, William R. ; Gurney, Howard...
European Urology Oncology. 7 (2024) 3 - p. 509-518 , 2024

Link: https://doi.org/10.1016/..

2

Publisher Correction: First-line talazoparib with enzalutam..:

Fizazi, Karim ; Azad, Arun A. ; Matsubara, Nobuaki...
Nature Medicine. 30 (2024) 5 - p. 1505-1505 , 2024

Link: https://doi.org/10.1038/..

3

Plain language summary of the results from the TALAPRO-2 st..:

Agarwal, Neeraj ; Azad, Arun A ; Carles, Joan...
Future Oncology. , 2024

Link: https://doi.org/10.1080/..

4

PHASE 3B STUDY DESIGN: COMPARING TREATMENT PREFERENCE BETWE..:

Enjeti, A. ; Fong, C. ; Paine, T....
Leukemia Research Reports. 21 (2024) - p. 100440 , 2024

Link: https://doi.org/10.1016/..

5

Maintenance durvalumab after first-line chemotherapy in pat..:

Fong, C. ; Patel, B. ; Peckitt, C....
ESMO Open. 9 (2024) 7 - p. 103622 , 2024

Link: https://doi.org/10.1016/..

6

Pembrolizumab plus Olaparib in Patients with Metastatic Cas..:

Yu, Evan Y. ; Piulats, Josep M. ; Gravis, Gwenaelle...
European Urology. 83 (2023) 1 - p. 15-26 , 2023

Link: https://doi.org/10.1016/..

7

Corrigendum to "Pembrolizumab plus Olaparib in Patients wit..:

Yu, Evan Y. ; Piulats, Josep M. ; Gravis, Gwenaelle...
European Urology. 83 (2023) 3 - p. e87 , 2023

Link: https://doi.org/10.1016/..

8

First-line talazoparib with enzalutamide in HRR-deficient m..:

Fizazi, Karim ; Azad, Arun A. ; Matsubara, Nobuaki...
Nature Medicine. 30 (2023) 1 - p. 257-264 , 2023

Link: https://doi.org/10.1038/..

9

Approach avoidance training versus Sham in veterans with al..:

Caudle, M. M. ; Klaming, R. ; Fong, C....
BMC Psychiatry. 23 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

10

Talazoparib plus enzalutamide in men with first-line metast..:

Agarwal, Neeraj ; Azad, Arun A ; Carles, Joan...
The Lancet. 402 (2023) 10398 - p. 291-303 , 2023

Link: https://doi.org/10.1016/..

11

P2.05-14 Understanding Genomic and Social Determinants of C..:

Carrot-Zhang, J. ; Fong, C. ; Waters, M....
Journal of Thoracic Oncology. 18 (2023) 11 - p. S313-S314 , 2023

Link: https://doi.org/10.1016/..

12

Impact of Concurrent Targeted Therapy and Immunotherapy on ..:

Beighley, A. ; Rahimian, J. ; Wong, A....
International Journal of Radiation Oncology*Biology*Physics. 117 (2023) 2 - p. e86 , 2023

Link: https://doi.org/10.1016/..

13

KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiratero..:

Todenhöfer, T. ; Piulats, J.M. ; Ferrario, C....
European Urology. 81 (2022) - p. S789-S790 , 2022

Link: https://doi.org/10.1016/..

14

Improvement in Dysphagia Outcomes Following Clinical Target..:

Vreugdenhil, M. ; Fong, C. ; Iqbal, G....
Clinical Oncology. 33 (2021) 12 - p. 795-803 , 2021

Link: https://doi.org/10.1016/..

15

Clinical and serological resolution of pembrolizumab associ..:

Clark, Hadleigh J ; Fong, Peter C C ; Ng, Kristine P L
Rheumatology. 61 (2021) 1 - p. e22-e24 , 2021

Link: https://doi.org/10.1093/..